Venezuela may abolish drug patents
Venezuelan President Hugo Chavez plans to invalidate some pharmaceutical patents, allowing local producers to create cheaper generic AIDS and cancer drugs. This could lead to future drug shortages. Dan Grech reports why.
More on International, Health, South - Central America
TEXT OF STORY
Steve Chiotakis: The Venezuelan President, Hugo Chavez, is on a tear against private enterprise. Earlier this month, his government banned Coke Zero over health concerns. And he's threatening to take over a Pfizer plant. His latest target: drug companies. From the Americas Desk at WLRN in Miami, here's Marketplace's Dan Grech.
Dan Grech: President Hugo Chavez says medical discoveries should belong to the world. His government plans to invalidate some pharmaceutical patents. Local producers would then create cheaper generic versions of popular AIDS and cancer drugs.
Ian Vasquez with the Cato Institute says Big Pharma may stop selling drugs to Venezuela. That could lead to shortages -- particularly of the newest medicines. But a boycott on drug exports wouldn't force Venezuela to recognize international property rights.
Ian Vasquez: A boycott at this point is almost superfluous since what the Venezuela government has declared is that their property is being stolen and going to be used anyway.
Vasquez says the real risk for pharmaceutical companies is Venezuela could sell its generic drugs to other countries. That could undermine the profits even further.
I'm Dan Grech for Marketplace.
Comments
Comment | Refresh
Post a Comment: Please be civil, brief and relevant.
Email addresses are never displayed, but they are required to confirm your comments. All comments are moderated. Marketplace reserves the right to edit any comments on this site and to read them on the air if they are extra-interesting. Please read the Comment Guidelines before posting.
You must be 13 or over to submit information to American Public Media. The information entered into this form will not be used to send unsolicited email and will not be sold to a third party. For more information see Terms and Conditions and Privacy Policy.